OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Platelet desialylation and TFH cells–the novel pathway of immune thrombocytopenia	110
Construction and characterization of chimeric FcγR T cells for universal T cell therapy	86
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	82
Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification	73
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation	72
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	70
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development	69
Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome	67
The roles of tissue resident macrophages in health and cancer	63
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	61
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting	56
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	48
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	46
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	43
Spliceosome inhibitor induces human hematopoietic progenitor cell reprogramming toward stemness	41
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	41
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	40
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	39
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	39
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability	39
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	39
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	36
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma	36
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera	36
Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain	35

DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	35
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	34
MiRNA-mediated EMT and CSCs in cancer chemoresistance	33
Targeting the integrated stress response in hematologic malignancies	33
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia	33
Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma	32
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	31